新的BA.2.75亚变体会导致新一轮COVID-19浪潮吗?

Q3 Pharmacology, Toxicology and Pharmaceutics
Suman Kumar Ray, Sukhes Mukherjee
{"title":"新的BA.2.75亚变体会导致新一轮COVID-19浪潮吗?","authors":"Suman Kumar Ray,&nbsp;Sukhes Mukherjee","doi":"10.2174/1871526523666230302103609","DOIUrl":null,"url":null,"abstract":"<p><p>The highly transmissible variation of COVID-19 has a new sub-variant known as a variant BA.2.75, which was initially discovered in India and is now found in at least 10 more countries. The World Health Organization (WHO) officials said that the new variant is actively being monitored. It has yet to be determined if the new variation is more clinically severe than its predecessors. It is known that the Omicron strain sub-variants are responsible for this rise in the worldwide COVID tally. It is too early to know if this sub-variant exhibits additional immune evasion characteristics, or is more clinically severe. The extremely contagious BA.2.75 sub-variant of Omicron has been documented in India, but there is no evidence yet that it has increased disease severity or dissemination. Many of the BA.2 lineage's sublineages form a unique collection of mutations as it evolves. A related branch of the BA.2 lineage is B.2.75. The size of genomic sequencing must be increased and maintained for the early detection of the variant strains of SARS-CoV-2. BA.2.75 is the second generation of BA.2 variations and has a high transmissibility level.</p>","PeriodicalId":13678,"journal":{"name":"Infectious disorders drug targets","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Can the New BA.2.75 Sub-variant Lead To One More COVID-19 Wave?\",\"authors\":\"Suman Kumar Ray,&nbsp;Sukhes Mukherjee\",\"doi\":\"10.2174/1871526523666230302103609\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The highly transmissible variation of COVID-19 has a new sub-variant known as a variant BA.2.75, which was initially discovered in India and is now found in at least 10 more countries. The World Health Organization (WHO) officials said that the new variant is actively being monitored. It has yet to be determined if the new variation is more clinically severe than its predecessors. It is known that the Omicron strain sub-variants are responsible for this rise in the worldwide COVID tally. It is too early to know if this sub-variant exhibits additional immune evasion characteristics, or is more clinically severe. The extremely contagious BA.2.75 sub-variant of Omicron has been documented in India, but there is no evidence yet that it has increased disease severity or dissemination. Many of the BA.2 lineage's sublineages form a unique collection of mutations as it evolves. A related branch of the BA.2 lineage is B.2.75. The size of genomic sequencing must be increased and maintained for the early detection of the variant strains of SARS-CoV-2. BA.2.75 is the second generation of BA.2 variations and has a high transmissibility level.</p>\",\"PeriodicalId\":13678,\"journal\":{\"name\":\"Infectious disorders drug targets\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Infectious disorders drug targets\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/1871526523666230302103609\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Pharmacology, Toxicology and Pharmaceutics\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infectious disorders drug targets","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1871526523666230302103609","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0

摘要

高传染性的COVID-19变体有一个新的亚变体,称为变体BA.2.75,最初在印度发现,现在至少在10个国家发现。世界卫生组织(WHO)官员表示,正在积极监测这种新变种。目前尚不清楚这种新的变异是否比以前的变异在临床上更为严重。众所周知,欧米克隆菌株亚变体是导致全球新冠肺炎病例增加的原因。要知道这种亚变体是否表现出额外的免疫逃避特征,或者在临床上更为严重,还为时过早。在印度已经记录了极具传染性的BA.2.75欧米克隆亚变体,但目前还没有证据表明它增加了疾病的严重程度或传播。许多BA.2谱系的亚谱系在进化过程中形成了独特的突变集合。BA.2谱系的一个相关分支是B.2.75。为早期发现SARS-CoV-2变异株,必须增加和保持基因组测序的规模。BA.2.75是BA.2的第二代变异,具有较高的遗传水平。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Can the New BA.2.75 Sub-variant Lead To One More COVID-19 Wave?

The highly transmissible variation of COVID-19 has a new sub-variant known as a variant BA.2.75, which was initially discovered in India and is now found in at least 10 more countries. The World Health Organization (WHO) officials said that the new variant is actively being monitored. It has yet to be determined if the new variation is more clinically severe than its predecessors. It is known that the Omicron strain sub-variants are responsible for this rise in the worldwide COVID tally. It is too early to know if this sub-variant exhibits additional immune evasion characteristics, or is more clinically severe. The extremely contagious BA.2.75 sub-variant of Omicron has been documented in India, but there is no evidence yet that it has increased disease severity or dissemination. Many of the BA.2 lineage's sublineages form a unique collection of mutations as it evolves. A related branch of the BA.2 lineage is B.2.75. The size of genomic sequencing must be increased and maintained for the early detection of the variant strains of SARS-CoV-2. BA.2.75 is the second generation of BA.2 variations and has a high transmissibility level.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Infectious disorders drug targets
Infectious disorders drug targets Pharmacology, Toxicology and Pharmaceutics-Pharmacology
CiteScore
3.10
自引率
0.00%
发文量
123
期刊介绍: Infectious Disorders - Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in infectious disorders e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal contains a series of timely in-depth reviews written by leaders in the field covering a range of current topics on drug targets involved in infectious disorders. As the discovery, identification, characterization and validation of novel human drug targets for anti-infective drug discovery continues to grow, this journal will be essential reading for all pharmaceutical scientists involved in drug discovery and development.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信